Indian drugmaker Biocon (BSE: 532523) subsidiary Biocon Biologics has announced a settlement and license agreement with the ...

Yesafili, a vascular endothelial growth factor inhibitor, is used to treat several different types of ophthalmology ...

Vascular endothelial growth factor inhibitors (VEGFIs) have transformed treatment paradigms for several malignancies. By ...

Biocon share price has gained 1.6% in one month, but the stock has declined 11% on a year-to-date (YTD) basis. Biocon shares have rallied 23% in one year and more than 46% in two years.

Biocon Biologics has reached a settlement with Regeneron, allowing the launch of Yesafili, its biosimilar eye drug, in the US ...

Biocon Biologics has reached a settlement and licensing agreement with Regeneron, clearing the way for the US ...

Biocon Biologics Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved JOBEVNE™ (bevacizumab-nwgd), a ...

Anemia is a common condition in premature infants, particularly those at risk for retinopathy of prematurity (ROP).

The FDA has approved bevacizumab-nwgd, a biosimilar to bevacizumab, for intravenous use across multiple cancer types.

Biocon Biologics has received the Food and Drug Administration’s green light for Jobevne (bevacizumab-nwgd), a biosimilar ...

Cardiac problems associated with vascular endothelial growth factor inhibitors occur frequently in patients with cancer.

A new method can be used to identify factors involved in the specialization of naïve endothelial cells to tissue-specific endothelial cells.